Medicago Produces VLP Vaccine Candidate for H7N9 Virus; Shares at Yr High

By Staff,

Shutterstock photo

Medicago Inc (MDG.TO) is at a yr high of 65 cents today, with more than 1 million shares changing hands.

Shares hit a new yr high of 73 cents in earlier trade.

The company this morning announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China.

"To our knowledge, Medicago is the first to produce a VLP vaccine candidate against this potential pandemic strain demonstrating our  ability to be a first responder in a pandemic scenario," said Andy Sheldon, President and CEO of Medicago.

"Current influenza egg based vaccine manufacturers can take up to six months to produce a vaccine for any new strain, we have proven once again that we can cut this development time drastically.This combined with our vaccine production capacity at our pilot facility in Canada and our commercial facility in North Carolina and our best-in-class efficacy results for our H5N1 vaccine, strongly positions Medicago as a key player in addressing a potential  pandemic."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks:

More from MT Newswires


MT Newswires

MT Newswires

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by